Third Rock’s Tango Gets $55M for CRISPR-Enabled Synthetic Lethal Cancer Combos

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.

You may also like

Third Rock and Friends Bet $110M On Thrive, a Hopkins-Inspired Cancer Screening Startup
Betting on Biotech IPOs? What If You Buy the Third Rock and ARCH Portfolios?
Third Rock’s Revolution Medicines Tears Apart Antifungals, Atom By Atom
Third Rock’s Obesity Hopeful, Ember Therapeutics, Closes Down